A 12-week double-blind multi-centre study of paroxetine and imipramine in hospitalized depressed patients.
Fifty-seven inpatients with major depression (DSM-III-R) entered a 12-week study comparing paroxetine and imipramine. Trends (not reaching statistical significance) in favour of paroxetine were seen on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Rating Scale (MADRS). The UKU Side Effect Rating Scale showed a significant difference in favour of paroxetine on reduced salivation. Global evaluation of side effect symptoms showed that significantly more paroxetine patients had no side effects, both in the investigators' and the patients' opinion. These results are in line with previous findings of paroxetine being an effective and well tolerated antidepressant.
Arminen
S L
SL
Rauha Hospital, Finland.
Ikonen
U
U
Pulkkinen
P
P
Leinonen
E
E
Mahlanen
A
A
Koponen
H
H
Kourula
K
K
Ryyppö
J
J
Korpela
V
V
Lehtonen
M L
ML
D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
D017374:Paroxetine; D007099:Imipramine